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Objective Determination of the extent of changes in quantitative resistance in Pseudo-
monas aeruginosa isolates from patients with cystic fibrosis over a period of approximately
2 years.
Methods Three hundred and ninety nine isolates of P. aeruginosa collected from 34
pediatric patients in the period between April 1994 and April 1996 were investigated.
During the 2 years the children were treated with a combination of a betalactam and an
aminoglycoside, approximately every 3 months. In between they received ciprofloxacin
orally, when required. The minimal inhibitory concentrations (MICs) of 38 clones of P.
aeruginosa defined by different patterns in macrorestriction analysis (pulse field gel
electrophoresis, PFGE) were established for 12 antibiotics: gentamicin, amikacin, tobra-
mycin, ciprofloxacin, levofloxacin, moxifloxacin, trovafloxacin, imipenem, meropenem,
ceftazidime, cefepime, and piperacillin by means of broth microdilution tests according
to DIN 58940.
Results Twenty-four of the 38 clones developed increased MIC values during the time
of observation especially for aminoglycosides and quinolones. Comparatively less aff-
ected were ceftazidime, imipenem and meropenem. An association between the number
of the intravenous treatment courses and the increase of the MIC values could not be
verified.
Conclusions A trend towards an increase of the MICs against antipseudomonal agents
was observed over a limited period of time. It is necessary to prevent this development
possibly by employing suitable combinations of antibiotics and the introduction of new
substances.
Keywords Pseudomonas aeruginosa, antibiotic resistance, minimal inhibitory concentrations
(MICs), cystic fibrosis
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I N T R O D U C T I O N
Cystic fibrosis (CF) is an autosomal recessive,
multisystem disease with Pseudomonas aeruginosa
as the major prognostic factor in chronic res-
piratory infection [1]. Once colonization is
established the eradication of this pathogen is
almost impossible owing to the nature of cystic
fibrosis itself and the appearance of mucoid
phenotypes of P. aeruginosa forming microcolonies
on the mucosal surfaces which are surrounded by
an abundant mass of the microbial exopolysac-
charide alginate [2,3]. This unique bacterial pro-
duct may present a polyanionic barrier to
antimicrobial agents so that their action is pre-
vented.
As a result of the repeated use of antimicrobial
agents in the management of cystic fibrosis, there
may be a subsequent emergence of resistant
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P. aeruginosa [8]. The objective of this study was to
investigate the gradual development of in vitro
antibiotic resistance over a period of 2 years in P.
aeruginosa isolates from CF patients and to deter-
mine changes in relation to the way the antimi-
crobial agents used were applied.
S U B J E C T S A N D M E T H O D S
Patients
Isolates of P. aeruginosa, 399 in number, collected
from 34 children, who regularly attended the CF
center at the Department of Pediatrics of the Uni-
versity of Leipzig between April 1994 and April
1996, were investigated. Most of the patients were
hospitalized either for regular 2-week courses or
for the treatment of acute exacerbations as a rule
with an intravenous combination of ceftazidime
and gentamicin. Altogether there were 83 intrave-
nous treatment courses in the period of investiga-
tion, for details see Figure 1. When deemed
necessary the children received oral ciprofloxacin
in between and nebulized aminoglycosides for
inhalation. The patients were followed up in the
outpatient clinic of the above mentioned depart-
ment.
Bacteriologic methods
Sputum samples or deep-throat swab specimens
were collected before and after the antibiotic treat-
ment. Isolated strains were assessed by morpho-
logic features, including pigment production, and
identified as P. aeruginosa by a positive oxidase
reaction and appropriate results with the API-20
NE system (Bio-Me´rieux, Nu¨rtingen, Germany).
The strains were stored in special vials (Micro-
bank, Mast, Liverpool, UK) at 208.
The P. aeruginosa strains were analyzed for dif-
ferent pyocin types by the spotting method as
described by Fyfe et al. [4] and pulse field gel
electrophoresis (PFGE) patterns by contour-
clamped homogeneous electric field electrophor-
esis as described earlier [5]. Genomic DNA was
subjected to the rare-cutting restriction enzyme
SpeI. Twenty-two patients were chronically colo-
nized with strains with the same PFGE pattern,
seven were transiently colonized with two or more
different types and five were permanently colo-
nized with two different types in the observed
period (details have been published elsewhere) [5].
As a result of the variable number of colonizing
strains we investigated 38 P. aeruginosa clones with T
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Table 2 Comparison of geometric mean (GM) values of the MICs (mg/L), standard deviation in brackets, between phenotypic non mucoid and mucoid P. aeruginosa isolate
GEN AMK TOB CIP LEV MOX TROVA IPM MEM CAZ CPM PIP
n-muc (n¼122) 5.6746
(0.97; 33.25)
11.5075
(4.1; 32.3)
0.9493
(0.32; 2.78)
0.2997
(0.09; 0.97)
0.6859
(0.19; 2.5)
2.4181
(0.76; 7.67)
0.3116
(0.07; 1.43)
0.7364
(0.27; 1.99)
0.1977
(0.06; 0.65)
1.3979
(0.34; 5.73)
2.3655
(0.73; 7.68)
3.3368
(0.49; 8.32)
Muc (n¼277) 3.1677
(0.78; 12.79)
7.4038
(2.99; 18.36)
0.6811
(1.5; 0.31)
0.3237
(0.1; 1.07)
0.7945
(0.22; 2.83)
2.4473
(6.84; 0.88)
0.386
(0.08; 1.81)
1.1275
(2.89; 0.44)
0.2157
(0.72; 0.06)
1.4681
(0.55; 3.93)
2.4968
(0.97; 6.44)
3.7062
(0.86; 18.8)
P-value 0.0001 0.0001 0.006 0.697 0.278 0.803 0.185 0.0001 0.268 0.090 0.842 0.119
n-muc, non-mucoid phenotype; muc, mucoid phenotype; P-value, Mann–Whitney U-test; GEN, Gentamicin; AMK, Amikacin; TOB, Tobramycin; CIP, Ciprofloxacin;
LEV, Levofloxacin; MOX, Moxifloxacin; TROVA, Trovafloxacin; IPM, Imipenem; MEM, Meropenem; CAZ, Ceftazidim; CPM, Cefepim; PIP, Piperacillin.
Table 3 MICs (mg/L), geometric mean, standard deviation in brackets, of 38 P. aeruginosa clones at the end of observation in relation to the duration of colonization in April
96.
GEN AMK TOB CIP LEV MOX TROVA IPM MEM CAZ CPM PIP
G 1 1.68
(4.8; 0.6)
5.66
(11.3; 2.8)
0.71
(1.4; 0.4)
0.18
(0.3; 0.1)
0.42
(1.0; 0.2)
1.41
(2.8; 0.7)
0.21
(0.5; 0.1)
1.42
(2.1; 0.9)
0.18
(0.6; 0.1)
1.68
(3.27; 0.86)
1.41
(2.1; 0.9)
2.38
(14.7; 0.4)
G 2 1.68
(7.3; 0.4)
5.19
(25.9; 1.0)
0.71
(2.3; 0.2)
0.23
(0.8; 0.1)
0.65
(2.5; 0.2)
1.41
(8.1; 0.2)
0.29
(1.3; 0.1)
0.71
(2.6; 0.2)
0.18
(0.4; 0.1)
1.54
(2.58; 0.92)
1.99
(4.6; 0.9)
4.76
(11.8; 1.9)
G 3 1.99
(4.4; 0.9)
5.79
(14.8; 2.3)
0.57
(1.2; 0.3)
0.16
(0.8; 0.0)
0.38
(1.7; 0.1)
1.45
(5.8; 0.4)
0.21
(1.2; 0.0)
0.69
(1.9; 0.2)
0.17
(0.6; 0.1)
1.32
(4.99; 0.35)
1.59
(5.8; 0.4)
2.76
(16.9; 0.5)
G 4 27.97
(328.9; 2.4)
19.34
(51.8; 7.2)
1.76
(6.3; 0.5)
0.53
(2.9; 0.1)
1.29
(5. 6; 0.3)
3.99
(9.6; 1.7)
0.78
(4.2; 0.2)
1.07
(3.5; 0.3)
0.21
(1.1; 0.0)
1.99
(10.61; 0.38)
5.14
(15.2; 1.7)
3.75
(26.3; 0.5)
P-value 0.0056 0.033 0.071 0.262 0.256 0.178 0.218 0.3 0.835 0.65 0.056 0.623
GEN, Gentamicin; AMK, Amikacin; TOB, Tobramycin; CIP, Ciprofloxacin; LEV, Levofloxacin; MOX, Moxifloxacin; TROVA, Trovafloxacin; IPM, Imipenem; MEM,
Meropenem; CAZ, Ceftazidim; CPM, Cefepim; PIP, Piperacillin.
Group 1 (G1) 0.5 years, n¼4; group 2 (G2): 0.5 – 2 years, n¼8; group 3 (G3): >2– 4 years, n¼14; group 4 (G4): >4 years, n¼12)
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Figure 2 MICs of ceftazidime and
moxifloxacin against Pseudomonas
aeruginosa clones with 38 PFGE-pat-
terns at the beginning of the investi-
gation (t ¼ 0; 38 isolates), after 1 year
(t ¼ 1 year; 31 isolates) and after 2
years (t ¼ 2 years; 19 isolates).
Figure 1 Antibiotics and combina-
tions of antibiotics used in 83 epi-
sodes of i.v. therapy.
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different PFGE patterns. Two to 31 isolates per
PFGE-pattern were isolated.
Minimal inhibitory concentration (MIC)
The MIC is defined as the lowest concentration of
an antimicrobial agent that prevents visible
growth of bacteria [6].
The MICs of 38 strains were established for 12
antibiotics: gentamicin (Serva, Heidelberg, Ger-
many), amikacin (Bristol-Myers Squibb, Munich,
Germany), tobramycin (Sigma, Munich, Germany),
ciprofloxacin (Bayer, Leuerkusen, Germany), levo-
floxacin (Daiichi, Aventis, Bad Soden, Germany),
moxifloxacin (Bayer), trovafloxacin (Pfizer, Karls-
ruhe,Germany), imipenem(MerckSharp&Dohme,
Haar,Germany),meropenem(AstraZeneca,Wedel,
Germany), ceftazidime (GlaxoSmithKline, Munich,
Germany), cefepime (Bristol) and piperacillin
(Lederle, Mu¨nster, Germany) by means of broth
microdilution tests according to DIN 58940 [6].
The interpretative categories with regard to the
breakpoints were fixed [6] as follows:
 gentamicin, tobramycin  1 mg/mL (s), 2–4 mg/
mL (i),  8 mg/mL (r);
 amikacin  4 mg/mL (s), 8–16 mg/mL (i),
 32 mg/mL (r);
 ciprofloxacin, levofloxacin, moxifloxacin, trov-
afloxacin  1 mg/mL (s), 2 mg/mL (i),  4 mg/
mL (r);
 imipenem ¼ 2 mg/mL (s), 4 mg/mL (i), ¼ 8 mg/
mL (r);
 meropenem ¼ 2 mg/mL (s), 4–8 mg/mL (i),
¼ 16 mg/mL (r);
 ceftazidime, cefepime ¼ 4 mg/mL (s), 8–16 mg/
mL (i), ¼ 32 mg/mL (r);
 piperacillin ¼ 4 mg/mL (s), 8–32 mg/mL(i), ¼
64 mg/mL (r).
Figure 3 MICs of ciprofloxacin and
levofloxacin against Pseudomonas aer-
uginosa clones with 38 PFGE patterns
at the beginning of the investigation
(t ¼ 0; 38 isolates), after 1 year (t ¼ 1
year; 31 isolates) and after 2 years (t
¼ 2 years; 19 isolates).
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R E S U L T S
Table 1 shows the susceptibility of the 38 P. aeru-
ginosa clones at the beginning of the observation.
When the geometric means were compared, tobra-
mycin showed about four times lower MICs than
gentamicin and about nine times lower MICs than
amikacin. Among the quinolones, ciprofloxacin
and trovafloxacin possessed the lowest MIC
values. They were two times lower than levoflox-
acin and seven times lower than moxifloxacin.
Cefepime was somewhat more active than cefta-
zidime. The geometric mean MIC of meropenem
showed the lowest value, being about five times
lower than that of imipenem.
The number of samples with the typical mucoid
colony morphology (n ¼ 277) was greater than
those without alginate production (n ¼ 122).
The mucoid isolates were, except for the
aminoglycosides, less susceptible to the anti-pseu-
domonal agents, but significance was only
achieved by imipenem (Table 2). The mucoid iso-
lates were significantly more susceptible to genta-
micin, tobramycin, and amikacin (the Mann–
Whitney U-test).
The mean time the patients were colonized with
P. aeruginosa was 3.8 years in April 1996. Four
patients were colonized for less than 0.5 years,
eight patients for 0.5–2 years, 14 patients for 2–
4 years and eight patients for more than 4 years.
The length of colonization correlated with increas-
ing MIC values, especially for aminoglycosides
and quinolones, a statistical significance was
reached for gentamicin and amikacin (Kruskal–
Wallis one-way test). Isolates from patients colo-
nized for more than 4 years accounted for this
Figure 4 MICs of gentamicin and
tobramycin against Pseudomonas aer-
uginosa clones with 38 PFGE patterns
at the beginning of the investigation
(t ¼ 0; 38 isolates), after 1 year (t ¼ 1
year; 31 isolates) and after 2 years (t
¼ 2 years; 19 isolates).
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statistical significance (Mann–Whitney-Test, a ¼
0.05, P <0.0083) (Table 3).
During the study period 24 clones showed an
increase of MIC values that resulted in alterations
of the qualitative susceptibility (from susceptible
to intermediate, from susceptible to resistant and
from intermediate to resistant), at least against one
of the investigated antibiotics. The extent of the
development of resistance differed for the inves-
tigated antibiotics. Ceftazidime, imipenem and
meropenem were less affected than the other sub-
stances.
Figures 2–5 show, in eight representative
examples, the gradual development of resistance
during the observed time. The MICs (geometric
mean) did not change the qualitative interpretative
categories except for levofloxacin (sensitive to
intermediate) and moxifloxacin (intermediate to
resistant). There were no correlations between the
number of parenteral antibiotic treatment courses
or the number of ciprofloxacin applications,
respectively, and the development of resistance
in 14 clones from 12 patients with at least four
parenteral antibiotic courses, and ten clones from
nine patients with at least four ciprofloxacin appli-
cations (Chi2 Test), respectively (Table 4). The
proportion of strains resistant to gentamicin and
amikacin increased in proportion to the amount of
inhaled gentamicin (Chi2 Test, gentamicin P ¼
0.0229; amikacin P ¼ 0.01; tobramycin P >0.05,
Table 5). For parenteral treatment the patients
received an intravenous combination, as a rule
consisting of ceftazidime (150 mg/kg/day) and
gentamicin (9 mg/kg/day). In between the chil-
dren were treated with long-term nebulized
gentamicin (80 mg/day) as a rule and, when nec-
essary, oral ciprofloxacin for 2 weeks (40 mg/kg/
day).
Figure 5 MICs of meropenem and
imipenem against Pseudomonas aeru-
ginosa clones with 38 PFGE patterns
at the beginning of the investigation
(t ¼ 0; 38 isolates), after 1 year (t ¼ 1
year; 31 isolates) and after 2 years (t
¼ 2 years; 19 isolates).
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D I S C U S S I O N
P. aeruginosa strains isolated from patients with
cystic fibrosis over time are often multiply resis-
tant. Emergence of resistance in strains isolated
from CF patients has been reported earlier [8].
Current epidemiological data on the prevalence
of antibiotic resistant P. aeruginosa infecting CF
patients in European countries other than Italy
[9] and Denmark [7] are rare.
Of the aminoglycosides, the P. aeruginosa iso-
lates investigated here were most susceptible to
tobramycin, followed by gentamicin and amika-
cin. Shawar et al. [10] reported that tobramycin has
good activity, even against multiply resistant P.
aeruginosa strains. Among the quinolones cipro-
floxacin showed the highest activity, followed by
trovafloxacin, levofloxacin and moxifloxacin.
Other authors reported similar results [11,12]. In
P. aeruginosa strains isolated from CF the efflux-
system MexC-MexD-OprJ and MexE-MexF-OprN
are the dominant mechanisms of resistance [13] to
fluoroquinolones.
According to previous studies [14], the carba-
penems have excellent activities, and meropenem
is about five times more active than imipenem. The
higher activity of meropenem could be related to
the lower induction of chromosomal beta-lacta-
mase, its ability to cross the outer membrane
through the OprD-Porin and an additional chan-
nel, and the additional target protein PBP3 [15–17].
With increasing time of colonization with P.
aeruginosa, the MICs increased, especially for ami-
noglycosides and the quinolones. It seemed that
the susceptibility of the clones remained relatively
constant during the first years of colonization. In
our study resistant P. aeruginosa isolates were
predominantly found in patients who were colo-
nized for more than 2 years.
A correlation between the number of courses of
parenteral antibiotic therapy and the development
of resistance could not be verified. Carmeli et al.
[18] suggested that treatment with ceftazidime is
associated with a relatively low risk of subsequent
emergence of resistance in P. aeruginosa, as com-
pared to other substances such as imipenem. This
is in accordance with our results. The low extent
of development of resistance to the carbapenems
in our study may be a result of the rare use of
these substances. There is no difference in resis-
tance induction by either elective or symptomatic
parenteral antibiotic therapy, as found by Elborn
et al. [19]. A correlation between the number of
courses of oral ciprofloxacin and the development
of resistance could not be shown in the study
presented here, possibly owing to the small sam-
ple size.
Intermittent inhalation of aminoglycoside anti-
biotics improves the pulmonary function and
decreases the density of P. aeruginosa in sputum
[20]. Our results suggest that long-term inhalation
of aminoglycosides may lead to an accumulation
Table 4 Proportion (%) of sensitive, intermediate and resistant P. aeruginosa strains with 14 different PFGE patterns (¼ 14
isolates pro cycle) in relation to the number of parenteral antibiotic courses
Number of i.v.
therapys GEN AMK TOB CIP LEV MOX TROVA IPM MEM CAZ CPM PIP
1
sensitive 14.3% 28.6% 85.7% 85.7% 71.4% 35.7% 85.7% 92.9% 100% 78.6% 78.6% 42.9%
intermediate 71.4% 57.1% 7.1% 7.1% 14.3% 14.3% 0% 0% 0% 14.3% 14.3% 50%
resistant 14.3% 14.3% 7.1% 7.1% 14.3% 50% 14.3% 7.1% 0% 7.1% 7.1% 7.1%
2
sensitive 14.3% 21.4% 57.1% 71.4% 64.3% 21.4% 71.4% 64.3% 92.9% 71.4% 64.3% 50%
intermediate 50% 57.2% 35.8% 21.5% 14.3% 28.6% 7.2% 28.6% 7.1% 28.6% 21.4% 35.7%
resistant 35.7% 21.4% 7.1% 7.1% 21.4% 50% 21.4% 7.1% 0% 0% 14.3% 14.3%
3
sensitive 14.3% 21.4% 71.4% 71.4 64.3% 28.6% 71.4% 57.1% 92.9% 71.4% 57.1% 50%
intermediate 57.1% 57.2% 21.5% 21.5% 14.3% 35.7% 7.2% 28.6% 7.1% 21.5% 35.8% 35.7%
resistant 28.6% 21.4% 7.1% 7.1% 21.4% 35.7% 21.4% 14.3% 0% 7.1% 7.1% 14.3%
4
sensitive 7.1% 7.1% 71.4% 92.9% 57.1% 28.6% 85.7% 85.7% 92.9% 78.6% 57.1% 50%
intermediate 57.2% 78.6% 28.6% 0% 28.6% 7.1% 0% 0% 7.1% 14.3% 35.8% 42.9%
resistant 35.7% 14.3% 0% 7.1% 14.3% 64.3% 14.3% 14.3% 0% 7.1% 0% 7.1%
GEN, Gentamicin; AMK, Amikacin; TOB, Tobramycin; CIP, Ciprofloxacin; LEV, Levofloxacin; MOX, Moxifloxacin;
TROVA, Trovafloxacin; IPM, Imipenem; MEM, Meropenem; CAZ, Ceftazidim; CPM, Cefepim; PIP, Piperacillin.
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of resistant strains. However, it has to be taken into
account that the children also received aminogly-
cosides parenterally. Burns et al. [21] also noted an
increase of MICs during chronic intermittent inha-
lation. The dominant mechanism of aminoglyco-
side resistance of P. aeruginosa isolated from cystic
fibrosis patients is reduced permeability [22]. The
concentration of inhaled drugs can be many times
higher than systemic concentrations [19]. Inhaled
antibiotic can lead to clinical improvement when
the P. aeruginosa isolates are above the threshold of
susceptibility for systemic application [20]. As
parenteral antibiotic therapy, consisting as a rule
of a betalactam and an aminoglycoside, still con-
stitutes an important component in the manage-
ment of P. aeruginosa infections in CF patients,
consideration of how to avoid the accumulation
of resistant strains is needed. Further studies are
necessary in order to investigate the influence of
inhalation therapy on the development of resis-
tance.
In summary, our results indicate that a moder-
ate increase of MICs for P. aeruginosa of several
therapeutically valuable compounds is detectable
over time. This increase affected least of all cefta-
zidime, imipenem and meropenem. Long-term
inhalation of aminoglycosides may lead to an
increase of resistant isolates of P. aeruginosa, espe-
cially with regard to amikacin and gentamicin, but
less distinctly against tobramycin. It may be advi-
sable to overcome these trends by using suitable
antibiotic combinations and by introducing new
and innovative substances in the treatment of
patients with CF.
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